Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.81 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.81 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067811 | 1.00 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 | |
| SCHEMBL3067510 | 0.93 | CHRNB2 (0.94) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL5654646 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL12205345 | 0.86 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL30665753 | 0.82 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 | |
| SCHEMBL1980777 | 0.82 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 | |
| SCHEMBL2067959 | 0.82 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 | |
| Tert-Butyl Formate SCHEMBL27685267 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA1CHRNA7 | |
| SCHEMBL30665760 | 0.81 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 | |
| SCHEMBL3361367 | 0.81 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387609-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| WO-2023023532-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | CHRNB2 4643/4885CHRNA4 4788/4885CHRNA1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.